Bergenbio ASA logo

BGBIO - Bergenbio ASA Share Price

NOK36.35 1.4  3.9%

Last Trade - 3:25pm

Sector
Healthcare
Size
Small Cap
Market Cap ÂŁ221.9m
Enterprise Value ÂŁ186.4m
Revenue ÂŁ18.5k
Position in Universe 578th / 1782
Bullish
Bearish
Unlock BGBIO Revenue
Momentum
Relative Strength (%)
1m -17.6%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -35.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 2.34 8.90 306 714
+379.2
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Bergenbio ASA revenues decreased from NOK8.7M to NOK0K. Net loss increased 10% to NOK48.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects R&D Expense - Government Grant decrease of 35% to NOK2.8M (income), Finance expense increase from NOK254K to NOK833K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BGBIO
Graphical History

Revenue

BGBIO Revenue Unlock BGBIO Revenue

Net Income

BGBIO Net Income Unlock BGBIO Revenue

Normalised EPS

BGBIO Normalised EPS Unlock BGBIO Revenue

PE Ratio Range

BGBIO PE Ratio Range Unlock BGBIO Revenue

Dividend Yield Range

BGBIO Dividend Yield Range Unlock BGBIO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BGBIO EPS Forecasts Unlock BGBIO Revenue
Profile Summary

Bergenbio ASA is Norway-based company that provides technology platforms used in the research and pre-clinical development of drug targets, associated biomarkers and therapeutics for the treatment of cancer. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The Company also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated January 31, 2008
Public Since April 7, 2017
No. of Shareholders: n/a
No. of Employees: 28
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Oslo Stock Exchange
Shares in Issue 74,798,305
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BGBIO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BGBIO
Upcoming Events for BGBIO
Frequently Asked Questions for Bergenbio ASA
What is the Bergenbio ASA share price?

As of 3:25pm, shares in Bergenbio ASA are trading at NOK36.35, giving the company a market capitalisation of ÂŁ221.9m. This share price information is delayed by 15 minutes.

How has the Bergenbio ASA share price performed this year?

Shares in Bergenbio ASA are currently trading at NOK36.35 and the price has moved by 0.178k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bergenbio ASA price has moved by 0.190k% over the past year.

What are the analyst and broker recommendations for Bergenbio ASA?

Of the analysts with advisory recommendations for Bergenbio ASA, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bergenbio ASA is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Bergenbio ASA next release its financial results?

Bergenbio ASA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Bergenbio ASA dividend yield?

Bergenbio ASA does not currently pay a dividend.

Does Bergenbio ASA pay a dividend?

Bergenbio ASA does not currently pay a dividend.

When does Bergenbio ASA next pay dividends?

Bergenbio ASA does not currently pay a dividend.

How do I buy Bergenbio ASA shares?

To buy shares in Bergenbio ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bergenbio ASA?

Shares in Bergenbio ASA are currently trading at NOK36.35, giving the company a market capitalisation of ÂŁ221.9m.

Where are Bergenbio ASA shares listed? Where are Bergenbio ASA shares listed?

Here are the trading details for Bergenbio ASA:

Country of listing: Norway
Exchange: OSL
Ticker Symbol: BGBIO
What kind of share is Bergenbio ASA?

Based on an overall assessment of its quality, value and momentum, Bergenbio ASA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bergenbio ASA share price forecast 2020?

Shares in Bergenbio ASA are currently priced at NOK36.35. At that level they are trading at 0.101% discount to the analyst consensus target price of 0.00.

Analysts covering Bergenbio ASA currently have a consensus Earnings Per Share (EPS) forecast of 0.903 for the next financial year.

How can I tell whether the Bergenbio ASA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bergenbio ASA. Over the past six months, the relative strength of its shares against the market has been 0.130k%. At the current price of NOK36.35, shares in Bergenbio ASA are trading at 40.17% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bergenbio ASA PE Ratio?

We were not able to find PE ratio data for Bergenbio ASA.

Who are the key directors of Bergenbio ASA?

Bergenbio ASA's management team is headed by:

Richard Godfrey - CEO
Sveinung Hole - CHM
Stener Kvinnsland - NID
Endre Kjaerland - OTH
Julia Schoelermann - OTH
Victoria Wills - OTH
Rune Skeie - CFO
Debra Barker - NED
Pamela Trail - NED
Grunde Eriksen - NED
Dominic Smethurst - OTH
Who are the major shareholders of Bergenbio ASA?

Here are the top five shareholders of Bergenbio ASA based on the size of their shareholding:

Meteva AS Corporation
Percentage owned: 26.07% (22.7m shares)
Mohn (Trond) Individual Investor
Percentage owned: 22.46% (16.5m shares)
Government of Norway Government Agency
Percentage owned: 8.38% (7.27m shares)
Investinor AS Private Equity
Percentage owned: 8.33% (7.27m shares)
Nordea Funds Oy Investment Advisor
Percentage owned: 4.78% (4.17m shares)
Similar to BGBIO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.